{
    "nct_id": "NCT06795022",
    "official_title": "A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T Cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants With Advanced or Metastatic Solid Tumours (RHEA-1)",
    "inclusion_criteria": "* Age ≥ 18 at the time of signing the informed consent.\n* GPC3 positive tumour as determined by a central laboratory using an analytically validated IHC assay.\n* Must have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n* Eastern Cooperative Oncology Group Performance status (ECOG PS): 0-1 at screening.\n* Predicted life expectancy of ≥ 12 weeks.\n* Adequate organ and bone marrow function measured within 28 days prior to first dose as defined by the protocol.\n* Contraceptive use by men or women should be consistent with local regulations, as defined by the protocol.\n* Confirmed advanced recurrent and/or metastatic and/or unresectable HCC, which is histopathologically proven based on the criteria established by the World Health Organization.\n* Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C.\n* Child-Pugh Score class A.\n* Previous therapy:\n\nPart A: Patients who have received at least one prior line of standard systemic therapy for HCC as per NCCN or other local scientific guidelines and for which a clinical study is the best option for next treatment based on prior response and/or tolerability and/or patient/investigator decision.\n\nPart B: Patients must not have received more than 1 prior line of systemic therapy in the advanced recurrent and/or metastatic setting.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Unresolved toxicity from prior anticancer therapy, including irAEs, of Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 2 except for vitiligo, peripheral neuropathy related to prior anti-cancer therapy, alopecia, endocrine disorders that are controlled with replacement hormone therapy and asymptomatic laboratory abnormalities.\n* Prior to enrolment, participation in another clinical study with an investigational product administered in the last 21 days or 5 half-lives whichever is shorter.\n* CAR-T cell therapy within the last 6 months prior to enrolment on this study.\n* Known allergy or hypersensitivity to AZD9793 or any of the excipients of the product as outlined in the IB.\n* Requires chronic immunosuppressive therapy (including steroids > 10 mg prednisone/day or equivalent).\n* Prior treatment with any therapy that is targeted to GPC3.\n* Received any therapy to treat cancer (including chemotherapy, biologics, cellular therapies) within 5 half-lives of an anticancer drug prior to the first dose of study treatment.\n* Received radiation within 14 days; palliative radiation to reduce the risk of tumour lysis syndrome (TLS) or CRS/neurotoxicity in participants with bulky disease is permitted.\n* Undergone a major surgical procedure within 14 days to allow adequate healing\n* Experienced unacceptable cytokine release syndrome (CRS) or Immune Effector Cell Associated Neurotoxicity (ICANS) following prior T cell engagers (TCE) or chimeric antigen receptor T (CAR-T) cell therapy.\n* Previous history of hemophagocytic lymphohistiocytosis (HLH) / macrophage activation syndrome (MAS).\n* Active or prior documented autoimmune or inflammatory disorders within 3 years of start of treatment.\n* Cardiac conditions as defined by the protocol.\n* History of thromboembolic event within the past 3 months prior to the scheduled first dose of study intervention.\n* Central nervous system (CNS) metastases or CNS pathology, as defined by the protocol, within 3 months prior to consent.\n* Infectious disease including active human immunodeficiency virus (HIV), and uncontrolled active systemic fungal, bacterial or other infection.",
    "miscellaneous_criteria": "Key"
}